Fibrin versus polyethylene glycol sealant: an experimental study in rabbits by Beer, Gertrude et al.
EXPERIMENTAL STUDY
Fibrin versus polyethylene glycol sealant: an experimental
study in rabbits
Gertrude M. Beer & Maria Schneller &
Heidi Cristina-Schmitz & Urs Hug &
Daniela Mihic-Probst
Received: 15 March 2008 /Accepted: 1 May 2008 / Published online: 10 June 2008
# Springer-Verlag 2008
Abstract Fibrin glue has been applied universally in
general surgery as an adhesive, hemostatic, or embolizing
agent. In reconstructive surgery, fibrin has been used
mainly for nerve and microvascular repair or as a substitute
for sutures in skin closure and skin grafting. Another area
of increasing use is in face-lift surgery, where the goal is to
improve hemostasis on the raw surfaces and to discourage
the occurrence of major hematomas. However, as most
components of the fibrin glue are derived from human or
bovine plasma, they may cause allergic reactions and
transmit infectious agents such as hepatitis or AIDS virus,
or prions such as the Creutzfeldt-Jakob disease agent. With
these risks in mind, we tested polyethylene glycol (PEG)
sealant, a recently introduced and purely synthetic vascular
sealant, as an alternative to fibrin glue. A 2×2 cm
subcutaneous pocket was created on the dorsal thighs of
ten New Zealand White rabbits by an incision medial to
the sciatic vein. The pockets were randomly filled with
either 0.2 ml of thawed fibrin glue or PEG sealant. After
the operation, the thighs were inspected macroscopically
for hematoma, seroma, or granuloma formation. Eleven
weeks later, the animals were killed, and the fibrin and
polyethylene glycol-filled pockets were harvested en bloc
with the overlying skin and processed for histological
examination. A swelling, viewed macroscopically, was
visible at the experimental site in three thighs of the fibrin
group, but in none of the PEG group. Only two specimens
of the fibrin group and five specimens of the PEG group
showed no signs of inflammation. All other specimens
revealed signs of chronic or granulomatous inflammation,
with no significant difference between the groups. This
experimental study showed that 11 weeks after application
of either fibrin or PEG sealant, signs of chronic or even
granulomatous inflammation were detectable in 2/3 of the
specimens in the fibrin group and in approximately 50%
of the specimens in the PEG group. Beyond the
comparable potential of both sealants to induce inflam-
matory tissue reactions, PEG sealant has some notable
advantages as it is purely synthetic and therefore carries
no risk of transmission of viral pathogens or prions. The
combination of this safety profile, the ease of application,
and the consistently good reported hemostatic results
obtained with PEG sealant makes it an interesting
alternative to fibrin glue in plastic surgery.
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Introduction
Commercially available fibrin glue is a topical agent that
initiates hemostasis by providing the components required
to activate the final substrate of the coagulation cascade. It
has been used in Europe for the past 40 years and is being
increasingly used in the US after having received US Food
and Drug Administration approval in 1998.
In the early fibrin glue era, researchers mixed their fibrin
components themselves, which was a time-consuming and
cumbersome procedure. Today, however, two simplified
forms of fibrin glue are available in pre-packed delivery
systems. The first system consists of four color-coded vials,
each containing one of the four components of fibrin glue,
where the preparation of the final glue first involves heating
the first two vials (the sealer protein and the fibrinolysis
inhibitor aprotinin) for 10 min and then mixing them. The
two remaining vials (thrombin and calcium chloride) are
also mixed and each of the two mixed components is filled
in a separate syringe in a dual injection system that ensures
simultaneous mixing and delivery to the tissues. The
second pre-packed, more convenient form is a ready-to-
use dual syringe system where the fibrin components are
already filled in their mixed forms. These syringes,
however, must be stored deeply frozen and thawed before
use.
In general surgery, fibrin has been applied universally as
an adhesive, hemostatic, or embolizing agent in countless
numbers of procedures. In reconstructive surgery, fibrin has
been used as a substitute for sutures in skin closure, for skin
grafting, and for nerve and microvascular repair. Nerve
repair has probably been the main clinical area where fibrin
glue has been routinely applied [1].
Another application of fibrin has been its increasing use
in face-lift surgery, with the goals of improving hemostasis
on the raw surfaces and discouraging the occurrence of
major hematomas [2]. As a result, fibrin may also decrease
edema and ecchymosis by closer apposition of the dissected
tissues, and may also eliminate postoperative wrinkling or
rippling of the skin, thus accelerating healing and minimiz-
ing patient discomfort [3]. At the same time, the application
of fibrin glue obviates the need for bulky dressings, drains,
ointments, wraps, and postoperative supportive garments
[4, 5].
Besides these obvious advantages in face lift surgery,
fibrin does have distinct disadvantages. One of these
disadvantages is the fact that some patients develop
localized skin necrosis, probably due to inconsistent
preparation, including failure to dissolve the glue material
properly during preparation, inhomogeneous and overly
thick areas of glue application, or improper patient
positioning with resultant pooling and clumping [6]. In
nerve surgery involving nerve repair, nerve-constricting
granulomas have also been reported after the application of
fibrin glue [7]. Another major disadvantage of fibrin glue is
the fact that it is derived from human and bovine plasma,
and may therefore potentially transmit infectious agents
such as viruses and prions [8]. Despite the fact that the risk
of transmitting viruses can be reduced by heating the glue
to 60°C and screening plasma donors for prior exposure,
fibrin glue can still potentially transmit prions such as the
Creutzfeldt–Jakob disease agent. To add to the disadvan-
tages, fibrin glue is contraindicated in individuals known to
be hypersensitive to bovine protein because of the possible
risk of anaphylaxis [9].
Bearing these risks of the application of fibrin glue in
mind, we looked for an alternative. Our criteria for an
alternative sealant were that it should be biodegradable,
biocompatible, and entail no risk of viral transmission. It
should also induce minimal tissue reaction, be readily
available, easy to apply, and function in a moist and bloody
environment, while inducing hemostasis and establishing a
strong and stable bond. Initial surgical reports have
indicated that polyethylene glycol (PEG) sealant, receiving
US food and drug administration approval in December
2003, possesses these characteristics [10–13]. PEG sealant
is a hydrogel that is formed when two derivatized PEG
powders are mixed together and applied to the tissues. To
examine whether PEG sealant could replace fibrin glue as a
hemostatic agent in raw surfaces and to determine its
possible value in plastic surgery, we compared the
subcutaneous behavior of both sealants in an experimental
rabbit model.
Materials and methods
Animal model
Ten female New Zealand White rabbits from a single breed
(Harlan, NL), with a mean weight of 3,990 g (range 3,650–
4,300 g) were chosen for the experiments. All surgical
procedures were completed in accordance with Swiss
animal protection laws for the use of laboratory animals
for research purposes.
Surgical procedure
For each operation, the rabbits were premedicated with
65 mg/kg ketamine and 4 mg/kg xylazine i.m., before oral
intubation and preoperative antibiotic prophylaxis with
0.8 ml/4 kg sulfonamide/trimetoprim. Anesthesia was
maintained with isoflurane, with O2 and N2O, under
spontaneous breathing.
The surgical procedure was identical on both sides. On
the dorsal thighs, the skin was shaved and a subcutaneous
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2×2 cm pocket was created by an incision medial to the
sciatic vein. No cauterization of bleeders was carried out.
The pockets were randomly filled with 0.2 ml of either
fibrin or polyethylene glycol sealants. Both sealants were
pre-filled in ready-to-use syringes already fitted into a
Duploject R system that enables their simultaneous mixing
and application through a special nozzle. Before applica-
tion, fibrin had to be thawed and warmed to room
temperature, whereas PEG could be used immediately as
it can be stored at room temperature. After application of
the sealants, the incisions were closed in two layers,
subcutaneously with polyglactin 910 5/0, and subcuticu-
larly with nylon 5/0.
After the operation, the dorsal thighs were macroscopi-
cally inspected for hematoma, seroma, or granuloma.
Eleven weeks later, the animals were killed and the fibrin
and polyethylene glycol-filled pockets were harvested en
bloc with the overlying skin, and processed for histolog-
ical examination. The specimens were examined for the
presence of scar tissue, fibrin, and inflammatory response.
They were fixed in buffered formaldehyde (4%) and
embedded in paraffin. From each paraffin block, 2-µm-
thick slides were cut and stained with hematoxylin and
eosin, Elastica van Gieson and acid fuchsin-orange G.
Elastica van Gieson stains for collagen and elastic fibers,
both of which are the major components of scar tissue,
while acid fuchsin-orange G is a specific stain for fibrin.
The specimens were examined for the presence or absence
of the two types of inflammation: chronic lympho-
histiocytic and granulomatous.
Results were analyzed using SPSS 13.0 (SPSS, Chicago,
IL). Nominal variables were summarized as % and were
compared between the left and right hind leg by the Chi-
square and the Fisher’s exact test. A p value of≤0.05 was
considered significant.
Results
On application, the gel formation for fibrin and PEG was
comparably quick, taking place within a few seconds
(<3 s). The wound healing was uneventful in all 20 thighs,
and there was no hematoma formation, seroma formation,
or skin necrosis in either group.
Due to the death of one rabbit before the final
examination, and technical problems in the histological
preparation of one specimen, there were ultimately eight
specimens in the fibrin group and nine in the PEG group.
Macroscopic examination
At the endpoint of the experiments, a swelling was visible
at the experimental site in three thighs (38%) where fibrin
glue had been applied (Fig. 1). In contrast, there was no
visible swelling or palpable tissue augmentation in any of
the thighs where PEG had been applied.
Histologic examination
Two (25%) specimens in the fibrin group and five speci-
mens in the PEG group (55%) showed no signs of
inflammation (Fig. 2a). Signs of chronic lympho-histiocytic
inflammation were seen in six specimens (75%) from the
fibrin group and in four specimens (45%) from the PEG
group (Fig. 2b). Granulomatous inflammations with epithe-
lioid and giant cells were encountered five times (55%) in
the fibrin group (Fig. 2c) and three times (33%) in the PEG
group. Although more specimens in the PEG group showed
no reaction and no signs of inflammation, the difference
was not statistically significant. Remnants of fibrin were
encountered in one case from the fibrin group and in two
cases from the PEG group. In all three cases, the fibrin was
intermingled with blood remnants; thus, it is likely that the
fibrin was derived from the rabbits themselves.
Discussion
The results of the study showed that, 11 weeks after
application of either fibrin or PEG sealant, 2/3 of the
specimens in the fibrin group and in approximately 50% of
the specimens in the PEG group showed signs of chronic or
even granulomatous inflammation with epithelioid and
giant cells. Only two specimens of the fibrin group and
five specimens of the PEG group revealed no signs of
inflammation at all.
Concerning fibrin glue, we saw similar results in
experimental gluing of the peroneal nerves of New Zealand
Fig. 1 Macroscopic view of the dorsal thigh of a New Zealand White
rabbit. Arrow indicates the bulging of the pocket 11 weeks after
application of fibrin glue
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White rabbits with the ready-to-use fibrin, resulting in a
considerable swelling at the coaptation site 11 weeks
after application (Fig. 3a). Histological examination
showed chronic granulomatous inflammation with nerve-
constricting scar tissue at the suture site.
At first glimpse, the long persistence of the ready-to-use
fibrin glue seems to be in clear contrast to the reports on the
presence of fibrin glue of other researchers. For example,
Smahel et al. [1] used fibrin for gluing the sciatic nerve of
rats at our clinic 20 years ago. They noticed that on the first
postoperative day, there were large amounts of fibrin
present in the gap at the periphery of the nerves. On the
third postoperative day, little remained of the previously
noted fibrin deposits on the glued nerves, and on the
seventh postoperative day, no fibrin was present in the
region of the junction site.
The main difference between our study and the study of
Smahel et al. is the different concentration of aprotinin in
the ready-to-use fibrin glue. While Smahel and others
varied the aprotinin (and thrombin) concentration according
to need and used a concentration of only 100 U/ml
aprotinin for gluing nerves, in our study, the predetermined
concentration of aprotinin in the ready-to-use fibrin was
3,000 KIU/ml. The thought of Smahel et al., that low
concentrations of aprotinin must be used to prevent fibrosis
Fig. 2 a Overview of a specimen with PEG: subcutaneous pocket
with (arrows) scar tissue (hematoxylin–eosin, ×15). Inset: in the
magnification of the scar tissue no inflammatory reaction can be seen
(Elatstica van Gieson, ×20). b Overview of a specimen with fibrin
remnants with chronic lympho-histiocytic reaction (hematoxylin–
eosin, ×15). Inset: arrowheads show the reaction in detail (acid
fuchsin-irange G, ×40). c Example of a specimen with fibrin shows
scar tissue with granulomatous inflammation with giant cells
(hematoxylin–eosin, ×60)
Fig. 3 Two examples of application of fibrin glue. a Nerve bonding
with fibrin glue 11 weeks after application of fibrin glue at a peroneal
nerve of a New Zealand white rabbit; there is a granulomatous
inflammation at the previous transection site. b Face lift surgery with
fibrin glue. Reopening the preauricular scar 1 year after the primary
lifting shows a whitish laminar scar formation, which permits an easy,
nearly bloodless dissection
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at the junction site of nerves, stems from the work of Matras
and Kuderna [14, 15], who performed the most extensive
research on the subject. Smahel et al. also composed the four
components of fibrin glue themselves, and tested (by varying
the aprotinin and thrombin concentrations) which concen-
trations of the single components gave the best results in
regard to a short duration of resorption (by timing the
fibrinolysis) and high strength of bond. Finally, Smahel et al.
and others [16] had recommended a concentration of not
more than 50 KIU/ml aprotinin in the fibrin glue to prevent
fibrosis at the coaptation site of nerves and thereby hindrance
of nerve regeneration while still guaranteeing sufficient bond
strength.
With the introduction of the two pre-packed delivery forms
of fibrin, many researchers decided to use them for the sake of
convenience and accepted the concentrations that are provided
in the kit and in the ready-to use syringes. However, it should
be noted that the provided concentration of 3,000 KIU/ml of
aprotinin is 60 times higher than what Kuderna et al.
recommended for their nerve-bonding technique in humans.
It is therefore not surprising that with such a high concentra-
tion of aprotinin many researchers had the same adverse
experience after application of this kind of fibrin as we had.
Moy [7], for example, compared the efficacy of fibrin glue to
nylon sutures in primary peripheral microneurorrhaphy of
the tibial nerve in adult New Zealand White rabbits. Even
after 18 weeks, the fibrin seal group exhibited a fibrous
thickening around each repair site. In the first postoperative
week, the fibrin seal group also exhibited areas of increased
cellularity composed of acute inflammatory cells. Moy
reasoned that some of this inflammation may be related to
the cross-species allogenic glue interaction with the recipi-
ent's biology, but he found that it appeared to resolve without
serious sequelae. In his results, he explained the significantly
decreased mean amplitude in the fibrin seal groups as
indicative of a lag in axonal regeneration. Hamm [17], using
the pre-packed fibrin glue, also noticed remnants of fibrin
glue with inflammatory cells 4 weeks after gluing sciatic
nerves in Albino Wistar rats, and a complete fibrotic
hindrance of axon regeneration. In contrast, Wieken [18]
and Narakas [19, 20] found no such hindrance of axon
regeneration.
Still other studies have used different concentrations of
aprotinin, thus confounding comparison of the results [21].
For example, Yin [22] injected fibrin glue with a concen-
tration of 1,000 KIU/ml bovine lung aprotinin around a
nerve repair site in the sciatic nerves of Sprague–Dawley
rats, and observed in histologic sections that the fibrin that
could be clearly visualized at 5 days could still be identified
at 15 days, but was no longer present after 30 days. He
made no comment as to fibrosis or inflammatory reactions.
Becker [23] even used fibrin glue with a concentration of
20,000 KIU/ml aprotinin in comparing skeletal muscle
metabolism after repair of divided rat sciatic nerves with
either microsurgical sutures or fibrin tissue adhesive, but
made no special comment as to the remnants of fibrin glue
after 60 or 150 days of application.
Face lift surgery is an application where a high
concentration of aprotinin, and thus the long persistence
of the fibrin glue, may turn out to be beneficial. In this
application, we observed (Fig. 3b) that even 1 year after the
primary lifting (even with the use of aerosolized fibrin
glue), we still encountered clear traces of the fibrin
application upon reopening the sutures. The remnants of
fibrin glue, a whitish laminar scar formation, were more
easily visible where a thicker layer of fibrin had been
applied. As a result, a secondary dissection on the level of
the fibrin glue was nearly bloodless, and the skin flaps
withstood considerable traction as they acted as “precondi-
tioned” flaps.
At a primary face lift, when thick layers of fibrin are
applied, the fibrin glue obviously acts as a barrier to
revascularization of the skin flaps and prevents normal
capillary growth in a timely fashion, with the danger of
impeding proper wound healing and ultimately causing
localized areas of skin necrosis [5]. The thicker and more
irregular the application of the fibrin glue is, the higher the
likelihood of skin necrosis. Yet, when the skin survives, it
becomes independent of the underlying tissues, thus
permitting more skin resection at a second surgery without
the danger of necrosis.
On the other hand, discussing the properties of PEG,
Hagberg et al. [10] examined the effectiveness of PEG for
managing anastomotic bleeding after implantation of Dacron
grafts during aortic reconstruction for nonruptured aneur-
ysms, and reported no adverse events related to the use of
PEG and in comparison to Gefoam/thrombin. PEG demon-
strated significantly better ultimate sealing properties.
A study by Glickman [11] stated that PEG sealant
inhibited anastomotic suture hole bleeding more rapidly
than fibrin and demonstrated good biocompatibility. In
another study by Cosgrove [12], who evaluated the safety
and efficacy of PEG for watertight dural repair, he found no
sealant-related adverse events. PEG provided an effective,
watertight closure when used as an adjunct to sutured dural
repair during cranial surgery.
All studies to date demonstrate that PEG is very effective
as a hemostatic agent in sealing suture holes in vascular grafts,
even in polytetraethylene (PTEE) grafts. It is well-known that
sealing of PTEE grafts represents the greatest challenge due to
leakage from holes created in the graft by needles during
suturing. There were no adverse events related to PEG in the
cited studies, supporting the overall benefit-to-risk ratio of
PEG for use in sealing of vascular grafts.
In our study, comparing the properties of fibrin and PEG
sealants, both led to chronic and even granulomatous
Eur J Plast Surg (2008) 31:243–248 247
inflammation at the application site, even 11 weeks after
application. Besides their comparable potential to induce
inflammatory tissue reactions, PEG sealant possesses some
notable advantages as it is purely synthetic and has no risk
of transmission of viral pathogens or prions. PEG can also
be stored at room temperature.
This safety profile, the ease of storage, and the reported
consistently good hemostatic results obtained with PEG
might make it an interesting alternative to fibrin glue in
plastic surgery.
Although the small number of experimental animals and
their thick skin makes this study purely preliminary, these
promising results lend support to the completion of a larger
study.
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